The estimated Net Worth of Hans Hull is at least $4.5 Milion dollars as of 10 July 2024. Hans Hull owns over 9,900 units of Pliant Therapeutics stock worth over $2,789,076 and over the last 4 years Hans sold PLRX stock worth over $1,711,553.
Hans has made over 8 trades of the Pliant Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Hans sold 9,900 units of PLRX stock worth $114,444 on 10 July 2024.
The largest trade Hans's ever made was selling 34,919 units of Pliant Therapeutics stock on 3 August 2023 worth over $698,729. On average, Hans trades about 6,145 units every 80 days since 2020. As of 10 July 2024 Hans still owns at least 227,494 units of Pliant Therapeutics stock.
You can see the complete history of Hans Hull stock trades at the bottom of the page.
Hans's mailing address filed with the SEC is C/O PLIANT THERAPEUTICS, INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 4 years, insiders at Pliant Therapeutics have traded over $16,925,448 worth of Pliant Therapeutics stock. The most active insiders traders include Group, Llc Green Jeremy Red..., Rock Ventures Iii, L.P.Thir... a Thomas A Mccourt. On average, Pliant Therapeutics executives and independent directors trade stock every 24 days with the average trade being worth of $221,612. The most recent stock trade was executed by Eric Lefebvre on 10 July 2024, trading 12,319 units of PLRX stock currently worth $142,408.
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Pliant Therapeutics executives and other stock owners filed with the SEC include: